CV07050101
CV07050101 Uses, Dosage, Side Effects, Food Interaction and all others data.
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).
| Trade Name | CV07050101 |
| Generic | CVnCoV |
| CVnCoV Other Names | CV07050101, SARS-CoV-2 mRNA vaccine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here CV07050101
